AstraZeneca Imfinzi combo improves survival in bladder cancer study (AZN:NYSE)
· seekingalpha.com
AstraZeneca says Imfinzi + enfortumab vedotin improved event-free and overall survival in muscle-invasive bladder cancer vs standard care.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...